Ownership and insider activity for Jazz Pharmaceuticals plc (JAZZ): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymph...
Price
| Price | $236.04 |
| Market Cap | $14.8B |
| Exchange | NASDAQ |
| Country | IE |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-01 | COZADD BRUCE C | S-Sale | 6,000 | $1.4M |
| 2026-09-10 | Patil Neena M | S-Sale | 1,200 | $289K |
| 2026-09-08 | GALA RENEE D | F-InKind | 1,967 | $485K |
| 2026-09-08 | GALA RENEE D | S-Sale | 2,000 | $486K |
| 2026-09-08 | Henderson Mary Elizabeth | F-InKind | 1,412 | $343K |
| 2026-09-08 | Henderson Mary Elizabeth | F-InKind | 15 | $4K |
| 2026-08-31 | Henderson Mary Elizabeth | F-InKind | 2,076 | $501K |
| 2026-08-31 | Henderson Mary Elizabeth | F-InKind | 16 | $4K |
| 2026-08-31 | Smith Mark Douglas | F-InKind | 14 | $3K |
| 2026-08-31 | Smith Mark Douglas | F-InKind | 1,692 | $408K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $366.0M | $386.0M | $309.6M | $637.3M | $1.06B | $591.4M | $881.5M | $1.51B | $2.41B | $1.39B |
| Short-term Investments | $60.0M | $215.0M | $515.0M | $440.0M | $1.07B | 0 | 0 | $120.0M | $580.0M | $1.05B |
| Receivables | $234.2M | $224.1M | $263.8M | $356.0M | $396.5M | $563.4M | $651.5M | $705.8M | $716.8M | $830.7M |
| Inventory | $34.1M | $43.2M | $53.0M | $78.6M | $95.4M | $1.07B | $714.1M | $597.0M | $480.4M | $417.0M |
| Total Current Assets | $748.1M | $968.3M | $1.23B | $1.63B | $2.84B | $2.61B | $2.61B | $3.44B | $4.63B | $4.17B |
| Property, Plant & Equipment | $107.5M | $170.1M | $200.4M | $270.9M | $257.1M | $343.4M | $301.4M | $235.0M | $227.0M | $258.7M |
| Goodwill | $893.8M | $947.5M | $927.6M | $920.0M | $958.3M | $1.83B | $1.69B | $1.75B | $1.72B | $1.83B |
| Intangible Assets | $3.01B | $2.98B | $2.73B | $2.44B | $2.20B | $7.15B | $5.79B | $5.42B | $4.76B | $4.43B |
| Total Assets | $4.80B | $5.12B | $5.20B | $5.54B | $6.54B | $12.30B | $10.84B | $11.39B | $12.01B | $11.66B |
| Accounts Payable | $22.4M | $24.4M | $40.6M | $47.5M | $26.9M | $100.3M | $90.8M | $102.8M | $77.9M | $122.1M |
| Short-term Debt | $36.1M | $40.6M | $33.4M | $33.4M | $246.3M | $31.0M | $31.0M | $605.0M | $31.0M | $1.03B |
| Total Current Liabilities | $257.4M | $293.9M | $345.5M | $364.5M | $653.7M | $809.3M | $933.2M | $1.54B | $1.04B | $2.24B |
| Long-term Debt | $1.99B | $1.54B | $1.56B | $1.57B | $1.85B | $6.02B | $5.69B | $5.11B | $6.08B | $4.33B |
| Total Liabilities | $2.92B | $2.41B | $2.45B | $2.43B | $2.88B | $8.33B | $7.75B | $7.66B | $7.92B | $7.34B |
| Retained Earnings | $528.9M | $918.0M | $841.0M | $1.07B | $1.16B | $830.2M | $733.6M | $878.7M | $1.13B | $646.2M |
| Total Equity | $1.88B | $2.71B | $2.76B | $3.11B | $3.66B | $3.97B | $3.09B | $3.74B | $4.09B | $4.32B |
| Total Debt | $2.03B | $1.58B | $1.60B | $1.77B | $2.25B | $6.15B | $5.81B | $5.79B | $6.16B | $5.42B |
| Net Debt | $1.60B | $980.0M | $771.8M | $693.9M | $116.6M | $5.56B | $4.93B | $4.17B | $3.17B | $2.98B |
| Working Capital | $490.7M | $674.3M | $888.5M | $1.27B | $2.19B | $1.80B | $1.67B | $1.90B | $3.59B | $1.92B |
Financial Health
| Debt / Equity | 0.92 |
| Current Ratio | 1.78 |
Profitability
| Return on Equity | -8.25% |
| Return on Invested Capital | 1.22% |
| Return on Assets | -3.05% |
| Gross Margin | 84.67% |
| Operating Margin | 31.05% |
| Net Margin | 20.45% |
Related companies: ABVX · AXSM · CAI · CYTK · HALO · MDGL · MRUS
Explore sector: Healthcare · Biotechnology
More sections of JAZZ: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks